Pernix Therapeutics Holdings Inc (NASDAQ:PTX)
| 3.24 Data as of May 17 |  -0.05 / -1.52%Today’s Change | 2.93 Today|||52-Week Range 9.20 | -58.19% Year-to-Date |
Latest PTX News | Press Releases
| Pernix Reports Loss in 1Q - Analyst Blog May 13 / Zacks.com |
Today’s Trading
| Previous close | 3.29 |
| Today’s open | 3.29 |
| Day’s range | 2.93 - 3.31 |
| Volume | 124,554 |
| Average volume (3 months) | 75,588 |
| Market cap | $123.7M |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/17/2013
Growth & Valuation
| Earnings growth (last year) | -114.71% |
| Earnings growth (this year) | +80.00% |
| Earnings growth (next 5 years) | -21.85% |
| Revenue growth (last year) | +1.16% |
| P/E ratio | NM |
| Price/Sales | 3.56 |
| Price/Book | 1.43 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CHTPChelsea Therapeutics... | -0.01 | -0.53% |
| FLMLFlamel Technologies ... | +0.09 | +1.97% |
| STMLStemline Therapeutic... | -0.25 | -1.67% |
| GENTGentium SpA | +0.04 | +0.45% |
Data as of 4:00pm ET, 05/17/2013
Financials
| Next reporting date | August 13, 2013 |
| EPS forecast (this quarter) | -$0.01 |
| Annual revenue (last year) | $61.3M |
| Annual profit (last year) | -$1.4M |
| Net profit margin | -2.30% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Other |
President, Chief Executive Officer & Director Cooper C. Collins, MBA |
Vice President- Supply Chain Management Robert H. Cline, Jr., PhD |
Corporate headquarters The Woodlands, Texas |
Forecasts
